Investment Summary |
|
|---|---|
| Date | 2021-11-05 |
| Target | IO Biotech |
| Sector | Life Science |
| Sellers(s) |
HBM Partners
Vivo Capital Idinvest Partners |
| Deal Type | IPO |
SEARCH BY
| Category | Private Equity Firm |
|---|---|
| Founded | 2001 |
| PE ASSETS | 2.1B USD |
| Size | Large |
| Type | Sector Focused |
HBM Partners is a private investment firm focused on investing in entrepreneurial biopharma and other healthcare-related companies in Europe, North America, India and other Emerging Markets. HBM looks to invest $5 to $50 million per transaction and will consider private and public companies. HBM Partners was established in 2001 and is headquartered in Zug, Switzerland.
| DEAL STATS | # |
|---|---|
| Overall | 29 of 38 |
| Sector: Life Science M&A | 27 of 34 |
| Type: IPO M&A Deals | 25 of 29 |
| Country: Denmark M&A | 1 of 1 |
| Year: 2021 M&A | 11 of 11 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2021-10-08 |
Pyxis Oncology
Boston, Massachusetts, United States Pyxis Oncology specializes in developing a differentiated portfolio of biologics, including antibody-drug conjugates (ADCs) and immunotherapies, to improve the lives of patients with difficult-to-treat cancers. Pyxis Oncology was founded in 2018 and is based in Boston, Massachusetts. |
Sell | - |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2021-11-11 |
Acrivon
Watertown, Massachusetts, United States Acrivon is a proprietary, streamlined approach to develop patient selection tumor biopsy tests, called OncoSignature tests. Company’s lead molecule ACR-368 is a potent, selective inhibitor of CHK1 and CHK2 which has shown deep durable single agent activity, including complete responses, in a proportion of patients across several Phase 2 studies of platinum-resistant ovarian cancer and in squamous cell cancers, including anal cancer for which FDA has granted orphan drug designation. Acrivon was founded in 2018 and is based in Watertown, Massachusetts. |
Buy | - |
| Category | Growth Capital Firm |
|---|---|
| Founded | 1996 |
| PE ASSETS | 6.4B USD |
| Size | Mega |
| Type | Sector Focused |
Vivo Capital is a healthcare investment firm focused on opportunities throughout the US and China. Specific areas of interest include biopharmaceuticals, specialty pharmaceuticals, and medical devices. The Firm looks to identify and work with companies at the development and commercial stage products in the US and at the revenue stage in China. Vivo Capital was established in 1997 and is headquartered in Palo Alto, California.
| DEAL STATS | # |
|---|---|
| Overall | 13 of 14 |
| Sector: Life Science M&A | 9 of 9 |
| Type: IPO M&A Deals | 10 of 10 |
| Country: Denmark M&A | 1 of 1 |
| Year: 2021 M&A | 4 of 4 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2021-10-21 |
Minerva Surgical
Santa Clara, California, United States Minerva Surgical is a medical technology company focused on developing next-generation technology for treating excessive menstrual bleeding. Minerva Surgical was formed in 2008 and is based in Santa Clara, California. |
Sell | - |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2022-04-13 |
Sierra Oncology
San Mateo, California, United States Sierra Oncology is a late-stage biopharmaceutical company based in San Mateo, California, on a mission to deliver targeted therapies that treat rare forms of cancer. Sierra Oncology was formed in 2003 and is based in San Mateo, California. |
Sell | £1.9B |
| Category | Private Equity Firm |
|---|---|
| Founded | 1997 |
| PE ASSETS | 7.6B EUR |
| Size | Mega |
| Type | Sector Agnostic |
Idinvest Partners is a European investment firm focused on investing in small to mid-sized companies at various stages of development. Idinvest segments its investment activity into three groups. These include venture and growth capital, private debt, and dedicated portfolios/funds. Idinvest's venture and growth capital group looks to invest directly in early stage companies with high growth potential. Idinvest's private debt group seeks to provide senior or subordinated debt to small and mid-sized companies pursuing growth objectives. Idinvest's dedicated portfolio/funds group looks to invest in private equity funds, acquire secondary fund positions, and directly co-invest alongside other private equity firms in established companies. Idinvest Partners was formed in 1997 and is based in Paris.
| DEAL STATS | # |
|---|---|
| Overall | 38 of 38 |
| Sector: Life Science M&A | 5 of 5 |
| Type: IPO M&A Deals | 10 of 10 |
| Country: Denmark M&A | 1 of 1 |
| Year: 2021 M&A | 3 of 3 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2021-05-18 |
SightCall
San Francisco, California, United States SightCall provides WebRTC Platform as a Service video calling services. SightCall was founded in 2007 and is based in San Francisco, California. |
Sell | - |
